These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28448657)

  • 21. Pharmacogenomics of cisplatin-induced ototoxicity.
    Mukherjea D; Rybak LP
    Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update.
    Scott EN; Joseph AA; Dhanda A; Tanoshima R; Brooks B; Rassekh SR; Ross CJD; Carleton BC; Loucks CM
    Ther Drug Monit; 2023 Dec; 45(6):714-730. PubMed ID: 37726872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
    Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
    Lee JW; Pussegoda K; Rassekh SR; Monzon JG; Liu G; Hwang S; Bhavsar AP; Pritchard S; Ross CJ; Amstutz U; Carleton BC;
    Ther Drug Monit; 2016 Aug; 38(4):423-31. PubMed ID: 26960170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
    Dillard LK; Lopez-Perez L; Martinez RX; Fullerton AM; Chadha S; McMahon CM
    Cancer Epidemiol; 2022 Aug; 79():102203. PubMed ID: 35724557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic impact of a genetic test for cisplatin-induced ototoxicity.
    Dionne F; Mitton C; Rassekh R; Brooks B; Ross C; Hayden M; Carleton B
    Pharmacogenomics J; 2012 Jun; 12(3):205-13. PubMed ID: 21502965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients.
    van der Schoot GGF; Westerink NL; Lubberts S; Nuver J; Zwart N; Walenkamp AME; Wempe JB; Meijer C; Gietema JA
    Eur J Cancer; 2016 May; 59():134-141. PubMed ID: 27033261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
    Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
    Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
    Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
    Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
    El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
    Sanchez VA; Shuey MM; Dinh PC; Monahan PO; Fosså SD; Sesso HD; Dolan ME; Einhorn LH; Vaughn DJ; Martin NE; Feldman DR; Kroenke K; Fung C; Frisina RD; Travis LB
    J Clin Oncol; 2023 Apr; 41(12):2211-2226. PubMed ID: 36626694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of early ototoxic effect in testicular-cancer patients treated with cisplatin by transiently evoked otoacoustic emission: a pilot study.
    Biró K; Baki M; Büki B; Noszek L; Jókúti L
    Oncology; 1997; 54(5):387-90. PubMed ID: 9260600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.
    Hjelle LV; Gundersen POM; Hellesnes R; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Bremnes RM; Haugnes HS
    Acta Oncol; 2018 Oct; 57(10):1392-1400. PubMed ID: 29775128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
    Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
    Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ototoxicity monitoring in children treated with platinum chemotherapy.
    Brooks B; Knight K
    Int J Audiol; 2018 Sep; 57(sup4):S34-S40. PubMed ID: 28737048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.
    Núñez-Torres R; Martín M; García-Sáenz JÁ; Rodrigo-Faus M; Del Monte-Millán M; Tejera-Pérez H; Pita G; de la Torre-Montero JC; Pinilla K; Herraez B; Peiró-Chova L; Bermejo B; Lluch A; González-Neira A
    JAMA Dermatol; 2020 Sep; 156(9):987-991. PubMed ID: 32756886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
    Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
    Mironovich OL; Bliznetz EA; Garbaruk ES; Belogurova MB; Subora NV; Varfolomeeva SR; Kachanov DY; Shamanskaya TV; Markova TG; Polyakov AV
    Vestn Otorinolaringol; 2018; 83(4):60-66. PubMed ID: 30113582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss.
    Pasquariello KZ; Dey JM; Sprowl JA
    Mol Pharmacol; 2021 Oct; 100(4):348-355. PubMed ID: 34330821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.